Celltrion launches $300m CB
South Korean biopharmaceutical company Celltrion approached investors on Wednesday evening with a $300m convertible bond, making its debut in the market after mandating JPMorgan as sole bookrunner of the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts